drugset / Trial / NCT03111381

Toradol to Reduce Ureteroscopic Symptoms Trial

NCT03111381

Phase 2 Completed 94 enrolled Yale University
RandomizedSingle-groupTriple-blindTreatment

Summary

Double blinded randomized controlled clinical trial to assess the impact of intraoperative Toradol on post-operative pain scores for patients undergoing ureteroscopy for urinary stone management.

Timeline

Start
2017-08-01
Primary completion
2020-06-01
Completion
2020-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketorolac Other / unclassified 15 mg Intravenous
Subject Ketorolac Other / unclassified 30 mg Intravenous

Indications